The contributions of cyclooxygenase-2 to tumor angiogenesis.
about
Bacteria and cancer: cause, coincidence or cure? A reviewChronic immune activation and inflammation as the cause of malignancyLipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancerReciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathologyEpigenetic regulations of inflammatory cyclooxygenase-derived prostanoids: molecular basis and pathophysiological consequencesThe immunobiology of prostanoid receptor signaling in connecting innate and adaptive immunityHepatitis C Virus Stimulates the Expression of Cyclooxygenase-2 via Oxidative Stress: Role of Prostaglandin E2 in RNA ReplicationCOX-2 and cancer: a new approach to an old problemTranscriptional regulation of COX-2: a key mechanism in the pathogenesis of nasal polyposis in aspirin-sensitive asthmatics?Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapyInhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expressionChronic arsenic exposure and angiogenesis in human bronchial epithelial cells via the ROS/miR-199a-5p/HIF-1α/COX-2 pathwayReal-time changes in 1H and 31P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin.Astragalus saponins downregulate vascular endothelial growth factor under cobalt chloride-stimulated hypoxia in colon cancer cells.Extracellular matrix, inflammation, and the angiogenic response.Microvessel density is a prognostic marker of human gastric cancer.Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC.Cyclooxygenases and lipoxygenases in cancer.Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer.Targeting 20-HETE producing enzymes in cancer - rationale, pharmacology, and clinical potentialCelecoxib and GABA cooperatively prevent the progression of pancreatic cancer in vitro and in xenograft models of stress-free and stress-exposed miceCOX-2 - a target for preventing hepatic carcinoma?Nitric oxide and redox mechanisms in the immune response.Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention.Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells.Anticancer activity of fish oils against human lung cancer is associated with changes in formation of PGE2 and PGE3 and alteration of Akt phosphorylationCyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications.Chemotherapeutic potential of diazeniumdiolate-based aspirin prodrugs in breast cancer.Inflammation as cause for scar cancers of the lung.Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers.Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis.Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma.Combined use of COX-1 and VEGF immunohistochemistry refines the histopathologic prognosis of renal cell carcinoma.Helicobacter pylori promotes angiogenesis depending on Wnt/beta-catenin-mediated vascular endothelial growth factor via the cyclooxygenase-2 pathway in gastric cancer.Molecular markers that predict response to colon cancer therapy.Mechanisms of disease: Prostate cancer--a model for cancer chemoprevention in clinical practice.Genetic ablation of cyclooxygenase-2 in keratinocytes produces a cell-autonomous defect in tumor formation.Elevated SP-1 transcription factor expression and activity drives basal and hypoxia-induced vascular endothelial growth factor (VEGF) expression in non-small cell lung cancer.Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in Vitro and in Vivo.
P2860
Q21245476-8A4FE728-3799-495C-BF40-F97F41924696Q24648532-4DDB3566-67DB-4C54-BC82-62972F1135E6Q24800010-7656BC42-26F4-4169-AF47-0919DBE324D1Q26825075-F81DC7B4-042C-4234-811E-7D30BEAE0CCCQ26862642-5836A2BC-31DD-4B0F-B230-1D508DF0286DQ27021651-CAC41643-7F6C-48C2-8028-1E3461F6B7A2Q27470314-0EAE9740-9F31-4D8D-A038-14CEACD12519Q28191533-1C04CB6A-B537-4F1C-99B9-EED9B1184BD2Q28195309-0AA69470-C646-4A88-875D-F281D8F285A0Q28195436-B60FDE00-5D9D-4E72-B867-14DDD6F5A122Q28199319-D544C1AA-F7F8-4E4A-8825-A84EF24DC40FQ28397396-093E74D6-E177-4213-965A-600C4B5D7519Q30744878-93446AB1-195B-4438-BC58-62A9BDB6B7EAQ31094570-7FCD0829-0E0F-4DCB-8A4F-81B6C2F94625Q33795730-88F729C2-067F-4A9A-AC73-9C64FB230C46Q33868722-F77814D2-5F23-494D-8838-0548472118EEQ34003141-BC4C8135-CF3A-4384-9895-615F84968B49Q34224752-FD83CF98-40E5-41D4-8421-E0AF632BB661Q34290118-CA89D8C8-A109-40D5-A5A4-6F7FDED251B8Q34331195-F5776C45-FE51-43E8-B725-34E97FF652B0Q34338086-0AE4E10E-7A63-4202-A055-983A54CF20BBQ34391552-63D1D135-E353-4119-B12C-90F7193F306CQ34837281-499AFA09-4A7B-4A5F-80E7-5550B29569B0Q35001939-7D51A7E9-8CA6-420D-9CBD-48AC235D0791Q35011895-76FD9ACE-227C-4C51-9670-45A7670C45ACQ35060329-F6C9161D-C2F4-4AD9-89D9-9CD4401DFF0DQ35389104-AD83CC36-294D-44F7-B34E-ECEFDDB0D9EEQ35588568-BDB472EB-FADE-4EEE-8C88-698A712DD0FBQ35638851-87656C9B-D50C-4637-8E43-7A5C380C3C78Q35702390-A4BA01A8-6CB5-404F-B14A-F8360CCB5E7FQ35741628-071555B6-CFF3-44A9-9B38-D6F68DEDA5CFQ35782469-BD069E3E-F4CB-4914-968A-F1DAF18A0F89Q35884306-53F07D5A-F7E7-4079-871D-1A9788A441E7Q36014320-1E659F8F-CFDB-4537-A766-D6FFFA534A73Q36023196-A1381AA3-7037-4EB1-BFC7-4CE8CE469C21Q36150356-775864CD-7BCD-45D0-9D43-F69B7EA064F8Q36304000-89293172-D821-4D4B-8A0C-5482D616B013Q36401953-0193242C-86C5-40B1-866E-70BB5AF37A83Q36407908-0D4CDD2A-F485-4762-B352-5DDCD25B3954Q36571885-2A64550B-C1DD-41F1-8B42-035B28436536
P2860
The contributions of cyclooxygenase-2 to tumor angiogenesis.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The contributions of cyclooxygenase-2 to tumor angiogenesis.
@ast
The contributions of cyclooxygenase-2 to tumor angiogenesis.
@en
The contributions of cyclooxygenase-2 to tumor angiogenesis.
@nl
type
label
The contributions of cyclooxygenase-2 to tumor angiogenesis.
@ast
The contributions of cyclooxygenase-2 to tumor angiogenesis.
@en
The contributions of cyclooxygenase-2 to tumor angiogenesis.
@nl
prefLabel
The contributions of cyclooxygenase-2 to tumor angiogenesis.
@ast
The contributions of cyclooxygenase-2 to tumor angiogenesis.
@en
The contributions of cyclooxygenase-2 to tumor angiogenesis.
@nl
P356
P1476
The contributions of cyclooxygenase-2 to tumor angiogenesis.
@en
P2093
P2888
P356
10.1023/A:1026575610124
P577
2000-01-01T00:00:00Z
P6179
1052178109